InflammX Therapeutics enters into option agreement with Bausch + Lomb
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.
(Image credit: AdobeStock/Rawpixel.com)
InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.
Under the terms of the option agreement, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on the achievement of specified development milestones.1
“We see tremendous potential in combining our resources and expertise with InflammX’s innovative approach to retinal disease treatment,” said Yehia Hashad, chief medical officer and executive vice president of Research & Development, Bausch + Lomb in the press release.1
Brian Levy, chief executive officer, InflammX Therapeutics shared insight into this decision and the potential outcomes, saying, “Partnering with Bausch + Lomb offers a unique opportunity to accelerate the development of our pipeline and bring our therapies to patients worldwide. We share a common vision of improving outcomes for individuals affected by retinal disease, such as iAMD, which represents a majority of patients diagnosed with AMD, and for which there is no currently approved treatment.”1
The agreement was signed in December 2024. No financial terms have been disclosed.1
